Analyst Kyle Mikson CFA from Canaccord Genuity maintained a Buy rating on Natera and keeping the price target at $195.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Kyle Mikson CFA has given his Buy rating due to a combination of factors that highlight Natera’s strong performance and growth potential. The company reported impressive revenue growth in the second quarter of 2025, significantly surpassing both internal estimates and market expectations. This was largely driven by record growth in Signatera test volumes, fueled by increased new patient starts.
Natera’s strategic initiatives, including advancements in colorectal cancer screening and artificial intelligence, further bolster its growth prospects. The company has also raised its revenue guidance for 2025, reflecting confidence in continued strong performance. Despite increasing revenue expectations, Natera has maintained its operating expense guidance, indicating efficient management. These factors, combined with potential future catalysts, underscore the company’s long-term growth potential, justifying the Buy rating.
In another report released today, Robert W. Baird also maintained a Buy rating on the stock with a $200.00 price target.